Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting – QNT Press Release

TOKYO, Nov 24, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED ) perampanel (product name: Fycompa) at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022.

Key data Presentations for perampanel include the:
– Results from a post hoc analysis of the phase III clinical trial (FREEDOM/342), which evaluated long-term efficacy of perampanel monotherapy by seizure type in the open-label extension (52 weeks) for epilepsy patients with focal-onset seizures ( FOS), ≥ 12 years of age without prior treatment history (poster number: 2.228)
– Real-world pooled analyzes of perampanel for pediatric patients (poster number: …

Full story available on Benzinga.com

Source link

Recommended For You

About the Author: News Center